Core Insights - Prenetics Global Limited has launched Daily Ultimate Essentials PRO, a clinical-grade version of its flagship health supplement, featuring enhanced potency and new flavors while maintaining the same price for customers [1][2][5]. Product Launch - The new PRO formula includes significant increases in key nutrients, such as Vitamin B12 (up 733% to 200mcg) and Cell Renewal (up 300% to 100mg), aimed at delivering clinical-grade nutritional impact [3]. - Two new flavors, Mango + Passionfruit and Lemon + Orange, have been introduced to cater to consumer demand for variety [1][4]. Customer Engagement - Daily Ultimate Essentials has received over 10,000 five-star reviews and achieved more than 670,000 customer purchases since its launch, indicating strong market acceptance [2]. - Existing subscribers will be automatically upgraded to the PRO formula at no additional cost, ensuring accessibility for all customers [5]. Nutritional Advancements - The PRO formula features bioactive forms of Vitamin B6 and Riboflavin, enhancing nutrient absorption and utilization [3]. - The addition of saffron extract as a new ingredient aims to support mood and cognitive clarity [3]. Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [6][7]. - IM8 has rapidly grown, surpassing $100 million in annualized recurring revenue within 11 months and is now available in over 30 countries [6].

Financial Data and Key Metrics Changes - The company achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4][14] - Fourth quarter revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit in Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13][14] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the clear driver of revenue, generating $60.1 million for the full year 2025 at a healthy 63% gross margin [14] - IM8 reached a $120 million annualized revenue run rate in its first year, with Q4 revenue of $27.4 million [4][9] - The average order value for new customers more than doubled from $110 in 2025 to approximately $233 in early 2026 [10] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, with the remaining 60% from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a 10%-15% revenue uplift in those markets [47] Company Strategy and Development Direction - The company completed a strategic pivot by divesting non-core assets to focus on becoming a pure-play consumer health leader [5][6] - The balance sheet is strong, with approximately $171 million in total liquidity and zero debt, allowing for investment in IM8's global expansion [8] - The company aims for adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, with a revenue guidance of $180 million-$200 million for 2026, representing nearly 300% year-over-year growth [15] - The company is excited about launching two new products in Q4 2026, which are expected to enter large total addressable markets [16][26] Other Important Information - The company ceased all Bitcoin purchases as of December 4, 2025, and will not engage in any future Bitcoin or crypto purchases [8] - Research coverage has been initiated by Roth Capital Partners and Sidoti & Company, both with buy ratings and price targets of $36 and $30 respectively [12] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management explained that the quarterly subscription option was well-received by consumers, providing savings and increasing average order value, which shortens the payback period for customer acquisition costs [20][21][22] Question: Timing and nature of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements, targeting large total addressable markets [26] Question: Revenue guidance and trends - Management confirmed continued momentum in January and stated that new products are not included in the revenue guidance of $180 million-$200 million [27][28] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, rolling out numerous ads weekly and optimizing based on performance [34][35][36] Question: Strategic M&A strategy - The focus is on organic growth, but the company remains open to strategic M&A opportunities if they align with business goals [39] Question: Revenue growth sources - The majority of growth is expected from acquiring new customers, with significant potential in the US market [45][46]

Prenetics Global (NasdaqGM:PRE) Q4 2025 Earnings call February 18, 2026 10:00 AM ET Company ParticipantsDanny Yeung - Co-Founder and CEOStephen Lo - CFOConference Call ParticipantsAlex Hantman - AnalystGeorge Kelly - Managing Director and Senior Research AnalystThomas Forte - Managing Director and Senior Consumer Internet AnalystOperatorWelcome to the Prenetics' Fourth Quarter and Full-Year 2025 Earnings Conference Call. As a reminder, this call is being recorded. Your hosts today are Danny Yeung, Chief Exe ...

Financial Data and Key Metrics Changes - Prenetics achieved record revenue of $92.4 million for the full year 2025, representing a 480% increase year-over-year [4] - Q4 revenue surged 457% year-over-year to $36.6 million, with a 55% sequential increase from Q3 [13] - Gross profit for Q4 grew over 800% year-over-year to $21.7 million, with a consolidated gross margin of 59% [13] - Adjusted EBITDA loss for Q4 was $2.3 million, a 70.4% improvement from the same period in the prior year [13] - Full year adjusted EBITDA loss improved by 27% to $13 million [14] Business Line Data and Key Metrics Changes - IM8 was the primary driver of revenue, generating $60.1 million for the full year 2025 at a gross margin of 63% [14] - IM8 reached a $120 million annualized revenue run rate within its first year, with Q4 revenue from IM8 at $27.4 million [4][9] - The average order value for new customers increased from $110 in 2025 to approximately $233 in early 2026 [11] Market Data and Key Metrics Changes - 40% of IM8's revenues came from the US, while 60% came from international markets across 30 different countries [10] - The company plans to localize its website in at least five different markets by Q2 2026, expecting a revenue uplift of 10%-15% in local markets [46][47] Company Strategy and Development Direction - Prenetics completed a strategic pivot to focus solely on consumer health by divesting non-core assets, enhancing its margin profile and financial position [5][6] - The company aims to achieve adjusted EBITDA profitability by Q4 2027, supported by strong unit economics and significant operating leverage [5][14] - Two new products are expected to launch by the end of Q4 2026, targeting large total addressable markets [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IM8, highlighting strong momentum and a clear path to becoming a billion-dollar global brand [16] - The company anticipates continued revenue growth driven primarily by customer acquisition, with significant opportunities in the US and international markets [44] Other Important Information - Prenetics has a total liquidity of approximately $171 million with zero debt, providing ample runway for investment in IM8's global expansion [7] - The company has ceased all Bitcoin purchases and will not engage in any future crypto purchases, holding 510 BTC for financial flexibility [7][8] Q&A Session Summary Question: Reasoning behind the 90-day offering - Management indicated that the quarterly subscription option was well-received by consumers, providing benefits for both sides, including upfront payment and reduced logistics costs [20][21] Question: Timing and characteristics of new product launches - Two new SKUs are planned for release by the end of Q4 2026, focusing on health and performance supplements in large markets [25] Question: Trends observed in January and guidance for IM8 - Management noted continued momentum in January, with new products not included in the revenue guidance of $180 million-$200 million for 2026 [26][27] Question: Customer acquisition costs and lifetime values - Customer acquisition costs are approximately $130, with a payback period of 3.4 months, and the average order value has increased significantly [32][33] Question: Use of AI in marketing - The company utilizes AI for digital marketing, generating a high volume of ads and optimizing performance based on algorithmic feedback [34][35] Question: Strategic M&A strategy - The focus remains on organic growth, with openness to strategic M&A opportunities if they align with the company's goals [38] Question: Revenue growth sources and localization impact - Most growth is expected from new customer acquisition, with localization efforts anticipated to yield a 10%-15% revenue increase in targeted markets [44][46]

Q4 & FY 2025 Earnings Presentation David Beckham Co-founded IM8 Brand with $120M+ ARR on a Billion- Dollar Path Executive Summary • Transformational Growth Achieved record revenue of $92.4M in FY25, driven by the explosive launch of IM8, which reached $120M ARR in its first year. • Strategic Pivot Complete Record-breaking growth driven by IM8 and strategic transformation Successfully divested non-core assets (ACT Genomics, Europa and Insighta) to become a pure-play consumer health leader focused on premium ...

Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW ...

Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the appointment of Dr. Darshan Shah as an independent director to its Board of Directors (the “Board”), effective February 16, 2026. Dr. Shah wi ...

Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026 NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the completion of the sale of its 35% equity interest in Insighta to Tencent for ...

Core Insights - Prenetics Global Limited (NASDAQ: PRE) has appointed Formula 1 driver Ollie Bearman as its Global Ambassador and shareholder, enhancing the brand's association with elite athletes committed to health excellence [1][3][8] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [11][12] - IM8 has rapidly grown to become one of the fastest-growing supplement brands globally, achieving over US$100 million in Annual Recurring Revenue within just 11 months of its launch [3][11] Product Highlights - IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement designed to replace 16 different supplements, and is NSF Certified for Sport, ensuring quality and safety for athletes [6][12] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [12] Athlete Partnership - Ollie Bearman, at just 20 years old, has already made a significant impact in Formula 1, including a historic debut with Ferrari, and has expressed strong belief in IM8's mission and products [5][9] - Bearman experienced notable performance benefits from using IM8's products, which contributed to his decision to invest in the brand [6][7] Market Position - IM8 is sold in over 30 countries worldwide and is backed by a Scientific Advisory Board comprising experts from prestigious institutions like the Mayo Clinic and Cedars-Sinai [9][11]

Core Insights - Prenetics Global Limited (NASDAQ: PRE) has appointed Formula 1 driver Ollie Bearman as its Global Ambassador and shareholder, enhancing the brand's alignment with elite athletes committed to health excellence [1][3][8] - IM8, co-founded by David Beckham, has rapidly grown to achieve US$100 million in Annual Recurring Revenue within just 11 months of its launch, establishing itself as a leading supplement brand [3][11] - Bearman, at 18, made a historic debut in Formula 1 with Ferrari, showcasing his potential as a top talent in motorsport [5][9] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 redefining the premium daily nutrition category through science-backed formulations [11][12] - IM8's Daily Ultimate Essentials is an all-in-one supplement designed to replace 16 different supplements, certified for sport, and free from common allergens [12] Athlete Partnership - Ollie Bearman experienced significant performance benefits from IM8's Daily Ultimate Essentials, which contributed to his decision to invest in the brand [6][7] - The partnership with Bearman reflects IM8's strategy to engage with athletes who prioritize scientifically validated nutritional support [3][9] Market Position - IM8 has become one of the fastest-growing supplement brands globally, with a strong foundation of scientific credibility supported by a Scientific Advisory Board from renowned institutions [9][11] - The brand is now sold in over 30 countries, indicating its expanding global presence [11]